Argenx calls it quits on Vyvgart Hytrulo Sjogren's disease trial
Argenx has discontinued a trial of Vyvgart Hytrulo in Sjogren's disease after a futility finding.
argenx
argenx is a antibodies company covered in the openbionews harvest.
Company Info
Recent News
Argenx's phase 2 celiac win tees up pivotal run for $2.2B drug
Argenx reported a Phase 2 win in celiac disease for a drug the headline values at $2.2 billion, teeing up a pivotal study.
Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
Endpoints News reports Argenx announced a Phase 3 win for Vyvgart Hytrulo in autoimmune myositis, setting up a potential next indication nod.
Argenx preps next potential Vyvgart nod after ph. 3 win
Fierce Pharma reports Argenx is heading to the FDA with Vyvgart for a potential blockbuster autoimmune indication after a Phase 3 win.
Argenx jumps on Phase 3 data for blockbuster Vyvgart
Argenx shares jumped on positive Phase 3 data for its blockbuster drug Vyvgart, reinforcing the drug's growth trajectory.
Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug
Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug.
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy.